Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Investor's Business Daily on MSN23h
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback